RNA · Insider Trading

Atrium Therapeutics, Inc. Common Stock

Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Every open-market purchase and sale reported by RNA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings

most recent

Open-Market Buys

code P

Sales

code S

Reporting Insiders

current holders

RNA — Recent Form 4 Transactions (latest 2026-09-22)

Filed	Insider	Role	Type	Shares	Value
2026-09-22	Husam Younis	Chief Scientific Officer	F	−11,216	−$100.38K
2026-09-22	W. Michael Flanagan	Director	F	−22,812	−$204.17K
2026-09-22	Sarah Boyce	Director	F	−126,418	−$1.13M
2026-09-22	Steven George Hughes	Chief Medical Officer	F	−21,459	−$192.06K
2026-09-22	Brendan R. Winslow	Chief Financial Officer	F	−6,742	−$60.34K
2026-09-22	Stephanie Kenney	See Remarks	F	−2,375	−$21.26K
2026-09-22	Kathleen P. Gallagher	See Remarks	F	−11,632	−$104.11K
2026-09-22	Rocio Martin Hoyos	Chief Strategy Officer	F	−8,320	−$74.46K
2026-04-22	Brendan R. Winslow	Chief Financial Officer	A	+30,000	—
2026-04-22	Husam Younis	Chief Scientific Officer	A	+30,000	—
2026-04-22	Rocio Martin Hoyos	Chief Strategy Officer	A	+30,000	—
2026-04-22	Stephanie Kenney	See Remarks	A	+30,000	—
2026-04-22	Steven George Hughes	Chief Medical Officer	A	+30,000	—
2026-04-22	Kathleen P. Gallagher	See Remarks	A	+102,500	—
2026-01-23	Steven George Hughes	Chief Medical Officer	Sell	−4,895	−$354.64K
2026-01-23	Teresa McCarthy	Chief Human Resources Officer	Sell	−2,929	−$212.21K
2026-01-23	W. Michael Flanagan	Chief Scientific Officer	Sell	−6,534	−$473.39K
2026-01-23	Michael F MacLean	Chief Financial Officer	Sell	−4,542	−$329.07K
2026-01-23	Arthur A Levin	Director	Sell	−1,758	−$127.37K
2026-01-23	Sarah Boyce	President and CEO	Sell	−14,387	−$1.04M
2026-01-09	Charles Calderaro III	Chief Technical Officer	Sell	−3,727	−$269.20K
2026-01-09	Michael F MacLean	Chief Financial Officer	Sell	−1,974	−$142.58K
2026-01-09	Steven George Hughes	Chief Medical Officer	Sell	−2,373	−$171.40K
2026-01-09	Teresa McCarthy	Chief Human Resources Officer	Sell	−1,965	−$141.93K
2026-01-09	W. Michael Flanagan	Chief Scientific Officer	Sell	−2,373	−$171.40K
2026-01-09	John B Moriarty	Chief Legal Officer	Sell	−2,374	−$171.47K
2026-01-09	Sarah Boyce	President and CEO	Sell	−8,576	−$619.44K
2025-12-22	Arthur A Levin	Director	G	−1,330	—
2025-12-19	Charles Calderaro III	Chief Technical Officer	MIXED	+13,524	−$699.01K
2025-12-19	John B Moriarty	Chief Legal Officer	MIXED	+29,176	−$1.93M
2025-12-19	Eric Mosbrooker	Chief Commercial Officer	MIXED	+24,010	−$3.45M
2025-12-19	W. Michael Flanagan	Chief Scientific Officer	MIXED	+13,805	−$984.26K
2025-12-19	Kathleen P. Gallagher	Chief Program Officer	MIXED	+30,634	−$2.97M
2025-12-19	Teresa McCarthy	Chief Human Resources Officer	MIXED	+21,702	−$1.24M
2025-12-19	Sarah Boyce	President and CEO	MIXED	−13,901	−$1.13M
2025-10-24	Steven George Hughes	Chief Medical Officer	MIXED	—	−$82.57K
2025-10-17	Teresa McCarthy	Chief Human Resources Officer	MIXED	—	−$556.26K
2025-10-07	Eric Mosbrooker	Chief Commercial Officer	MIXED	—	−$238.38K
2025-09-23	Steven George Hughes	Chief Medical Officer	MIXED	—	−$67.17K
2025-09-17	Steven George Hughes	Chief Medical Officer	MIXED	—	−$59.89K
2025-09-17	Teresa McCarthy	Chief Human Resources Officer	MIXED	—	−$286.04K
2025-09-12	W. Michael Flanagan	Chief Scientific Officer	MIXED	—	−$494.30K
2025-09-09	Troy Edward Wilson	Director	MIXED	−15,000	−$1.29M
2025-09-05	Sarah Boyce	President and CEO	MIXED	—	−$2.44M
2025-09-05	Eric Mosbrooker	Chief Commercial Officer	MIXED	—	−$249.54K
2025-09-02	Kathleen P. Gallagher	Chief Program Officer	Sell	−188	−$8.91K
2025-08-29	Sarah Boyce	President and CEO	MIXED	—	−$1.20M
2025-08-22	Steven George Hughes	Chief Medical Officer	MIXED	—	−$80.03K
2025-08-15	Michael F MacLean	Chief Financial Officer	Sell	−30,914	−$1.32M
2025-08-15	Teresa McCarthy	Chief Human Resources Officer	MIXED	—	−$242.23K

RNA — Current Insider Holders

Insider	Role	Shares Held	Value
Sarah Boyce	President and CEO	138,668	$1.12M
Kathleen P. Gallagher	See Remarks	119,729	$963.82K
Steven George Hughes	Chief Medical Officer	51,638	$415.69K
Husam Younis	Chief Scientific Officer	41,441	$333.60K
Rocio Martin Hoyos	Chief Strategy Officer	38,340	$308.64K
Brendan R. Winslow	Chief Financial Officer	36,859	$296.71K
Stephanie Kenney	See Remarks	33,085	$266.33K
W. Michael Flanagan	Chief Scientific Officer	31,974	$257.39K

RNA Insider Trading FAQ

Who are the insiders at RNA?

8 officers, directors and 10%+ beneficial owners currently report holdings in RNA via SEC Form 4.

Are RNA insiders buying or selling?

Across the 50 most recent Form 4 filings for RNA, 0 were open-market purchases (code P) and 15 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.

How current is RNA insider data?

Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent RNA filing is dated 2026-09-22.

How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the RNA quote page; the site-wide leaderboard is on the insider transactions hub.